Spotlight on Galantamine in Alzheimer???s Disease*
- 1 January 2003
- journal article
- research article
- Published by Springer Nature in Disease Management and Health Outcomes
- Vol. 11 (2) , 125-128
- https://doi.org/10.2165/00115677-200311020-00006
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Assessment of Health Economics in Alzheimer??s Disease (AHEAD)PharmacoEconomics, 2002
- Cholinergic Adverse Effects of Cholinesterase Inhibitors in Alzheimer??s DiseaseDrugs & Aging, 2001
- Galantamine is an allosterically potentiating ligand of the human α4/β2 nAChRActa Neurologica Scandinavica, 2000
- A 5-month, randomized, placebo-controlled trial of galantamine in ADNeurology, 2000
- Galantamine in ADNeurology, 2000
- Cholinesterase Inhibitors for the Treatment of Alzheimer??s Disease in the ElderlyDrugs & Aging, 2000
- Selectivity of Cholinesterase InhibitionCNS Drugs, 1999
- Cholinesterase Inhibitors in the Treatment of Alzheimer??s DiseaseDrug Safety, 1998
- Current Concepts in the Pathogenesis of Alzheimer’s DiseaseThe American Journal of Medicine, 1997
- Alzheimer's DiseaseJournal of Aging and Health, 1995